Epcoritamab gains positive opinion from CHMP for lymphoma therapy
24 Jul 2023
Drug ApprovalClinical StudyCell TherapyImmunotherapyAccelerated Approval
Preview
Source: Pharmaceutical Technology
AbbVie’s epcoritamab is intended to treat adult patients with relapsed/refractory DLBCL. Credit: AbbVie Inc.
AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for epcoritamab (TEPKINLY) to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
The CHMP has recommended granting conditional marketing authorisation for epcoritamab as a single agent for this indication following two or more lines of systemic therapy.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Zilovertamab Vedotin in Follicular Lymphoma GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Atezolizumab in Follicular Lymphoma GlobalData
View allCompanies IntelligenceAbbVie IncC H M P INCView all
The investigational IgG1-bispecific antibody has been developed leveraging the DuoBody technology of Genmab.
This technology directs cytotoxic T-cells selectively to obtain an immune response toward target cell types.
The company’s application for epcoritamab approval was based on data from the pivotal EPCORE NHL-1 Phase I/II study.
This multi-centre and open-label trial assessed epcoritamab’s preliminary efficacy and safety in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including DLBCL.
The overall response rate, evaluated by an independent review committee, was the trial’s primary endpoint.
AbbVie haematology therapeutic area head and vice-president Mariana Cota Stirner stated: “We are pleased with the recent CHMP positive opinion for epcoritamab, as it represents an important step in our journey to develop a potential core therapy for people living with B-cell malignancies, such as DLBCL.”
Epcoritamab is currently awaiting approval in the European Union (EU). Once approved, it will be marketed under the brand name TEPKINLY in all EU member states and in Iceland, Norway and Liechtenstein.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.